Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer by Simpson, GR et al.
Combination of a fusogenic glycoprotein, pro-drug activation
and oncolytic HSV as an intravesical therapy for superficial
bladder cancer
GR Simpson*,1,6, A Horvath1,6, NE Annels1, T Pencavel2, S Metcalf1, R Seth2, P Peschard2, T Price3, RS Coffin3,
H Mostafid4, AA Melcher5, KJ Harrington2 and HS Pandha1
1Oncology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK; 2Targeted Therapy Team, Institute of Cancer Research, London,
UK; 3BioVex Inc, 34 Commerce way, Woburn, MA, USA; 4North Hampshire Hospital, Basingstoke, UK; 5Institute of Molecular Medicine, St James’s
University Hospital Leeds, Leeds, UK
BACKGROUND: There are still no effective treatments for superficial bladder cancer (SBC)/non-muscle invasive bladder cancer.
Following treatment, 20% of patients still develop metastatic disease. Superficial bladder cancer is often multifocal, has high
recurrences after surgical resection and recurs after intravesical live Bacillus Calmette–Gue´rin. OncovexGALV/CD, an oncolytic herpes
simplex virus-1, has shown enhanced local tumour control by combining oncolysis with the expression of a highly potent pro-drug
activating gene and the fusogenic glycoprotein.
METHODS: In vitro fusion/prodrug/apoptotic cell-based assays. In vivo orthotopic bladder tumour model, visualised by computed
microtomography.
RESULTS: Treatment of seven human bladder carcinoma cell lines with the virus resulted in tumour cell killing through oncolysis,
pro-drug activation and glycoprotein fusion. OncovexGALV/CD and mitomycin C showed a synergistic effect, whereas the
co-administration with cisplatin or gemcitabine showed an antagonistic effect in vitro. Transitional cell cancer (TCC) cells follow an
apoptotic cell death pathway after infection with OncovexGALV/CD with or without 5-FC. In vivo results showed that intravesical
treatment with OncovexGALV/CD þ prodrug (5-FC) reduced the average tumour volume by over 95% compared with controls.
DISCUSSION: Our in vitro and in vivo results indicate that OncovexGALV/CD can improve local tumour control within the bladder, and
potentially alter its natural history.
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Bladder cancer is the fourth most common malignancy in men,
with an estimated 70 530 new cases and 14 680 deaths in the USA in
2010 (http://www.cancer.gov). Approximately 70% of these
patients initially present with superficial bladder cancer (SBC)
(Kirkali et al, 2005). The standard treatment for patients with SBC
is transurethral resection of the bladder tumour, followed by
adjuvant intravesical instillations with chemotherapy and/or
immunotherapy BCG (Bacillus Calmette–Gue´rin). The probabil-
ities of recurrence and progression in non-muscle invasive bladder
cancer at 5 years after standard treatment range from 31 to 78%
(Sylvester et al, 2006). These rates illustrate the modest success of
currently available treatments and underline the need for
improved therapies.
Oncolytic herpes simplex virus (HSV) vectors have shown
promising efficacy against a wide variety of malignancies, both
in vitro and in vivo and clinical trials for patients with metastatic
colorectal, head and neck, breast, and prostate cancer, melanoma,
and glioma have been completed (Kasuya et al, 2005).
OncovexGALV/CD is a third generation oncolytic HSV-1 that
combines oncolysis with the expression of a highly potent
pro-drug activating gene (yeast cytosine deaminase/uracil phos-
pho-ribosyltransferase fusion (Fcy::Fur)) and the fusogenic
glycoprotein from gibbon ape leukaemia virus (GALV). ICP34.5
deletion within the backbone of OncovexGALV/CD result in tumour
selective viral replication (Liu et al, 2003). ICP34.5 mutants in
which both copies of the gene are mutated are incapable of
replicating in neurons, but can replicate in and destroy glioma
cells in vitro and in vivo (Andreansky et al, 1996). The precise
mechanism for growth of ICP34.5 mutants in each tumour type is
not fully understood, but it is known from knockout mouse studies
that deletions and mutations in PKR and the IFN receptors allow
ICP34.5 mutant growth (Leib et al, 1999, 2000), and that these
mutations and deletions have been found in a number of tumour
types (Haus, 2000). This suggests that the deregulation of different
and/or multiple pathways in different tumour types allow tumour
selective growth of ICP34.5 mutants (review in Simpson and Coffin
(2008)). In addition, a deletion of ICP47 increases the antitumour
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immune response in the presence of HSV and places the Us11 gene
under immediate-early promoter control, which enhances growth
of HSV ICP34.5 mutants in tumour cells (Liu et al, 2003). Previous
studies with OncovexGALV/CD have shown enhanced cell killing and
tumour shrinkage (in vitro and in vivo) within tumours derived
from head (and neck), colon, pancreas, lung and glioma tissue
(Simpson et al, 2006; Price et al, 2010; Wong et al, 2010). A version
of this virus expressing GM-CSF has also shown promising results
in clinical phase I-II trials (Hu et al, 2006; Kaufman and Bines,
2010) and is currently in clinical phase III for the treatment of
melanoma and head and neck.
Bladder cancer is potentially an ideal tumour model for novel
therapies because intravesical delivery is able to expose the tumour
to high concentrations of virus. In addition, the umbrella cell layer
(i.e., the luminal surface of the urothelium) of the bladder is not
rapidly dividing and should therefore be resistant to infection and
lysis by replication-competent oncolytic viruses, which selectively
infect and replicate within rapidly dividing cells. Therefore, we
studied the effect of OncovexGALV/CD in combination with 5-FC/
chemo agents on bladder malignancies in vitro and in vivo in an
orthotopic rat bladder cancer model.
MATERIALS AND METHODS
Viruses and cell lines
The viruses used in the study were previously described by
Simpson et al (2006) and constructed. OncovexGFP (backbone
virus) and OncovexGALV/CD stocks were supplied by BioVex Inc.
(Woburn, MA, USA). Human bladder carcinoma cells (EJ, T24,
RT112) and baby hamster normal kidney cells (BHK-21) were
purchased from American Tissue Culture Collection (ATCC,
Manassas, VA, USA). Other human bladder carcinoma cells
(VMVUB-I, TCCSUP-G, 5637, KU19-19) were kindly given by
Professor Margaret Knowles (Cancer Research UK Clinical Centre,
Leeds, UK). The rat bladder carcinoma cell line (AY-27) was kindly
given by Dr Ronald B Moore (University of Alberta).
Fusion assay
The transitional cell cancer (TCC) cells were infected with
OncovexGALV/CD or OncovexGFP at MOI between 10–0.0001 and
incubated at 37 1C for 48 h. Cells were then either fixed and stained
with Glutaraldehyde, Crystal Violet, (Sigma, St Louis, MO, USA) or
treated with MTS reagent (Promega, Madison, WI, USA).
Prodrug-activating assay
The TCC cells were infected with OncovexGALV/CD or OncovexGFP at
MOI between 1–0.01. After 30min at 37 1C/5% CO2, the virus was
removed, and full growth media containing 5-FC (C4H4FN2O; Sigma)
was added and incubated for 48 h at 37 1C/5% CO2. The cell
supernatant was transferred into a fresh tube, and the cell debris was
removed by centrifuging. The supernatants were added to a fresh
tube and heat activated at 60 1C for 10min. The resulting super-
natants were allowed to cool to room temperature and added to test
cells. Cells were then either fixed and stained using Glutaraldehyde,
Crystal Violet, (Sigma) or treated with MTS reagent (Promega).
In vitro synergy assay
The effect of combination of agents on cell proliferation was
assessed by calculating combination index (CI) values using
CalcuSyn software (Biosoft, Cambridge, UK). Derived from the
median-effect principal of Chou and Talalay, the CI provides a
quantitative measure of the degree of interaction between two
agents. A CI of 1 denotes an additive interaction, 41 antagonism,
and o1 synergy. Experiments were done as described for the in
vitro survival assay using 4, 2, 1, 0.5 and 0.25 times the calculated
ED50 of each agent in a constant ratio checkerboard design.
Determination of cell death
Caspase 3 and 7 activity was detected on EJ cells which were
infected with either OncovexGALV/CD or OncovexGFP (with or
without 5-FC/5-FC metabolites) by Caspase Glo 3/7 reagent
(Promega). Apoptotic Z-VAD fmk inhibiter (50 uM) and Necrosis
inhibiter (20mM) Fructose was obtained from Sigma.
Orthotopic rat bladder tumour model
All procedures were approved by United Kingdom Home Office.
Fischer F344 female rats were purchased from B&K Universal or
Harlan Ltd. The animals were placed in a supine position and were
anesthetised with Isoflurane. The catheter (18-gauge BD Venflon)
was inserted into the bladder via the urethra. To facilitate the
tumour seeding, the bladder mucosa was damaged by instillation
with 0.1N hydrochloric acid followed by a rinse with 0.1N sodium
hydroxide for neutralisation. The bladder was washed five times
with PBS. A suspension of freshly harvested AY-27 HVEM cells
(1.5–2.5 106 cells) was then instilled and maintained in the
bladder for 1 h. After 1 h, the catheters were removed, and the rats
were allowed to void spontaneously.
Immunohistochemistry for Ki67
Paraffin sections were cut at 4 mm, dewaxed, and rehydrated before
being subjected to heat-mediated antigen retrieval in a microwave
using citrate buffer (10mM, pH 6.0). Ki67 (ab16667, Abcam,
Cambridge, UK) was diluted 1 : 100 in 1% BSA in PBS and
incubated on the sections overnight at room temperature in a
humidity chamber. The bound primary antibody was detected
using the Vectastain Elite ABC peroxidase system kit (VECTOR
Laboratories, Burlingame, CA, USA) followed by DAB detection
(DAKO, Glostrup, Denmark). To test the specificity of immunos-
taining, the primary antibody was omitted. Under this condition,
no staining was identified.
All animal studies were approved by the University of Surrey
ethical review board.
RESULTS
Human bladder TCC cell lines are sensitive to viral HSV
oncolysis, which is enhanced by the expression of GALV
glycoprotein
A panel of seven TCC cell lines were tested for viral HSV oncolysis.
High viral replication of the oncolytic HSV (OncovexGALV/CD) was
observed in all seven TCC cell lines with viral plaque detected as
low as 0.1–0.001 MOI. This HSV viral replication led to a strong
tumour cytotoxcity effect, which was detected by MTS assay at an
MOI as low as 0.001 (data not shown). The expression of GALV
glycoproteins enhanced this viral tumour selective killing in four
out of the seven TCC cell lines infected with OncovexGALV/CD.
Gibbon ape leukaemia virus expression led to the formation of
multinucleated syncytia, which were then surrounded with cells
showing the more classic HSV-1-mediated effect, (EJ cells, T24
cells, VMCUB-I cells, and 5637 cells) (Figure 1A). To study whether
the formation of multinucleated syncytia increased the cytopathic
effect of this virus (OncovexGALV/CD) when compared with the
backbone virus (OncovexGFP), in vitro MTS assays were carried
out. Lower levels of MTS activity were seen with OncoVEXGALV/CD
than OncovexGFP on infected EJ (42–54% decrease in cell survival,
Po0.000), T24 (35–45%, Po0.000), VMCUB-I (36–37%,
Po0.000), and 5637 (35%, Po0.000) cells. This suggests that the
presence of GALV env R-increased tumour cell killing (Figure 1B).
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Fcy::Fur expression converts 5-FC to 5-FU metabolites
within human bladder TCC cell lines in vitro
Fcy::Fur is a fusion of two yeast genes CD and UPRT, which
metabolises 5-FC more efficiently than either gene alone. To study
the cell killing effects of 5-FC metabolites on TCC cells, we infected
human EJ cells with OncovexGALV/CD or OncovexGFP in the presence
or absence of 5-FC for 48h at 37 1C. The cell supernatants were then
heat inactivated to neutralise the virus and added to fresh EJ cells for
a further 72h at 37 1C. In the presence of supernatants from EJ cells
infected with OncovexGFP no cell death was seen with or without
5-FC (Figure 2A). However, in the presence of supernatant cells
exposed to both OncovexGALV/CD þ 5-FC, effective cell killing was
seen (Figure 2A). Results were similar in a range of human bladder
tumour cell lines, including RT112 cells, TCCSUP-G cells, 5637 cells,
KU19-19 cells (data not shown). MTS assays were used to quantitate
the effects of prodrug activation therapy on bladder tumour cells
in vitro. EJ cells were the most susceptible to prodrug activation
therapy (Figure 2B). A 55% decrease in tumour cell survival was
detected on EJ cells at the concentration of 100mmol 5-FC
(Figure 2B), which decreased further to 78% at 600mmol 5-FC
(Po0.000) (Figure 2B). RT112 and KU19-19 cells showed moderate
sensitivity for OncovexGALV/CD prodrug activation therapy. In
between 600–1000mmol 5-FC, these cell lines showed around 70%
decrease in tumour cell survival (Figure 2B). Finally, TCCSUP-G and
5637 cells showed the lowest sensitivity for this prodrug activation
therapy, around 53% decrease in tumour cell survival at 1000mmol
5-FC (1000mmol, Po0.000) (Figure 2B). From these results, we
concluded that five out of seven TCC cells were sensitive to
metabolites of 5-FC after infection with OncovexGALV/CD (in the
presence of 5-FC) (Figure 2B).
OncovexGALV/CD and chemotherapeutic agent mitomycin C
(MMC), show synergistic interaction on bladder TCC
tumour cell lines, but not with cisplatin or gemcitabine
Currently, the three mostly clinically used intravesical chemo-
therapy agents for bladder cancer are MMC, cisplatin, and
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Figure 1 Fusogenic glycoprotein cytotoxic killing of bladder TCC cells. EJ, T24 VMCUB-I and 5637 cells were infected with OncovexGFP or OncoVexGALV/CD
at various MOIs and incubated at 37 1C/5% CO2 for 48 h, then assayed by crystal violet staining (A) or MTS assay (B) (Promega). Average cell survival was
calculated as a percentage compared with untreated cells (Unpaired student t-test comparing GFP Vs GALV/CD P-values: EJ (MOI 10 Po0.000, MOI 1
Po0.000), T24 (MOI 0.1 Po0.000, 0.01 Po0.000), VMCUMB-I (MOI 0.1 Po0.000, 0.01 Po0.000), 5637 (MOI 0.1 Po0.000, 0.01 Po0.000).
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gemcitabine. The effect of a combination of OncovexGALV/CD and
chemotherapy on cytotoxicity was therefore assessed for signifi-
cance by isobologram analysis by calculating CI values (see
Materials and Methods). Chemotherapy and OncovexGALV/CD were
administered to cells concomitantly. We tested TCC cells including
EJ, T24, TCCSUP-G, and KU19-19. We observed synergistic cell
killing with OncovexGALV/CD and MMC on EJ (ED50 0.77±0.05),
T24 (ED50 0.65±0.07) and KU19-19 (ED50 0.78±0.01) TCC cells
(Table 1). However, a combination of OncovexGALV/CD and
cisplatin/gemcitabine was antagonistic on EJ, (or T24, or
TCCSUP-G) cells at most ED5090. An exception to this was
OncovexGALV/CD and gemcitabine on T24 cells at high dose
(Table 1). This high dose synergy with OncovexGALV/CD and
gemcitabine was not seen on two other TCC cell lines (EJ and
KU19-19, Table 1). The results indicate that the co-administration
of OncovexGALV/CD and MMC showed a synergistic effect, whereas
the co-administration with cisplatin or gemcitabine showed an
antagonistic effect in vitro.
HSV replication is enhanced by the expression of GALV
glycoprotein on TCC cells
To address whether GALV-related fusion affected HSV replication
in TCC cells, OncovexGALV/CD and control OncovexGFP virus stocks
were prepared on EJ cells. The resulting stocks were replated onto
BHK cells, which do express the Pit-1 receptor that allows GALV-
related fusion (Sommerfelt and Weiss, 1990). The results show that
infection of EJ cells with OncovexGALV/CD showed a log higher
enhanced viral replication compared with control virus (Figure 3A,
P¼ 0.000). This confirms previous results seen in fibrosarcoma
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Figure 2 Prodrug activation in TCC cells infected OncovexGALV/CD. EJ, RT112, TCCSUP-G, 5637, and KU19-19 cells were infected with OncovexGFP and
OncovexGALV/CD at MOI of 0.1 and no virus control. After 30min at 37 1C/5% CO2, the virus was removed, and 1ml of FGM containing 5-FC (C4H4FN2O;
Sigma) at different concentrations (0-1400 mmol l – 1) was added and incubated for 48 h at 37 1C/5% CO2. The cell supernatants were then heat inactivated
and added to 1 x 104 fresh target cells and incubated at 37 1C/5% CO2 for 72 h and assayed by fixing and staining with glutaraldehyde/crystal violet (A) or
MTS assay (Promega) (B). Average cell survival was calculated as a percentage compared with untreated cells (unpaired student t-test comparing GALV/
CDþ or - 5-FC P-values: EJ (300mmol Po0.000, 600 mmol Po0.000), RT112 (800 mmol Po0.000, 1000mmol Po0.000), TCCSUP-G 1200 mmol Po0.000,
1400mmol Po0.000), 5637 800 mmol Po0.000, 1000 mmol Po0.000), KU19-19 (800mmol Po0.000, 1000mmol Po0.000).
OncGALV/CD as an intravesical therapy for bladder cancer
GR Simpson et al
499
British Journal of Cancer (2012) 106(3), 496 – 507& 2012 Cancer Research UK
T
ra
n
sl
a
ti
o
n
a
l
T
h
e
ra
p
e
u
ti
c
s
(HT1080) (Simpson et al, 2006). We predict that the process of
fusion allows more cellular resources to be obtained, which aids
viral replication.
HSV replication on TCC cells is not inhibited by 5-FC but
can be inhibited by 5-FC metabolites
The conversion of 5-FC to 5-FU results in an inhibition of
host DNA replication that might be expected to also inhibit
HSV. This was investigated on EJ cells by infecting them with
OncovexGALV/CD at various MOI with or without 600mM 5-FC. The
resulting infected lysates were then titred on BHK cells and showed
no significant difference in titre with or without 5-FC, Figure 3B. In
contrast, if EJ cells were exposed to the metabolites of 5-FC at the
point of infection with OncovexGALV/CD a dramatic drop in viral
replication was seen over 10-fold (Figure 3C, P-value (MOI 0.1)
0.005). Our results suggest that primary oncolytic HSV replication
is not inhibited by the conversion of 5-FC to 5-FU by Fcy::Fur in EJ
cells, but subsequent rounds of infection may be.
TCC cells follow an apoptotic cell death pathway after
infection with OncovexGALV/CD with or without 5-FC
Transfection of viral fusogenic membrane GALV in tumour cells
results in non apoptotic death (Bateman et al, 2000; Higuchi et al,
2000; Galanis et al, 2001; Linardakis et al, 2002; Lin et al, 2010).
Apoptosis is triggered early in a HSV-1 infection. During the later
stages of the virus life cycle, anti-apoptotic proteins such as ICP4,
ICP6, US11, gD, and gJ (Nguyen and Blaho, 2007) are produced
allowing the cells to assemble viral progeny before apoptotic cell
death (Nguyen and Blaho, 2007). The expression of CD-UPRT in
the presence of 5-FC also results in apoptotic death within tumour
cells (Gopinath and Ghosh, 2008). In our study, apoptotic death
was measured in EJ cells by measuring caspase activity. EJ cells
were infected with OncovexGALV/CD or OncovexGFP with or without
5-FC/5-FC metabolites and caspase 3 and 7 activity were measured
using caspase Glo 3/7 reagent (Promega). At the early time point
(24 h), both OncovexGALV/CD and OncovexGFP infection of EJ cells
showed limited caspase 3 and 7 activity compared with cells
exposed to 5-FC or 5-FC metabolites (Figure 4A). At later time
points, the caspase signal in HSV-infected cells rose in comparison
with cells exposed to prodrug therapy (Figure 4A), suggesting that
the caspase assay has not picked up viral-driven early apoptosis
owing to the fact that the virus has got through more than one
round of replication at 24 h and that anti-apoptotic viral proteins
inhibited its signal until the later stage of the viral life cycle. It was
interesting to see that OncovexGALV/CD þ 5-FC produced a caspase
signal similar to the 5-FC metabolites, which suggests that early
prodrug therapy induced caspase activity as much as its later
metabolites (Figure 4A). In addition, viral anti-apoptotic proteins,
failed to inhibit prodrug-induced caspase activity (Figure 4A) and
this early prodrug-induced caspase activity did not inhibit viral
replication (Figure 3B). When comparing caspase activity between
the oncolytic HSV expressing GALV glycoprotein and the back-
bone virus, no difference was seen at the early time points (24,
48 h, Figure 4A), a slight increase was seen with GALV expression
at 72 h, but this was not statistically significant (72 h, Figure 4A,
P¼ 0.06). It was concluded that GALV glycoprotein expression did
not alter caspase activity in infected EJ cells.
Caspase inhibiter blocks OncovexGALV/CD cell death
pathway in bladder TCC cells in vitro. In contrast, a
necrosis inhibiter fails to inhibit such cell death
To establish whether OncovexGALV/CD cell death is a purely
apoptotic-driven process, infected EJ cells were exposed to
Z-VAD fmk (a pan caspase inhibiter), after which samples were
assayed for lactate dehydrogenase activity, a marker for cytotoxic
Table 1 (a) Summary of in vitro therapy data; (b) Interaction of Oncovexgalv/CD and mitomycin C on three TCC cell line; (c) Interaction of Oncovexgalv/CD
and cisplatin on three TCC cell line; (d) Interaction of Oncovexgalv/CD and gemcitabine on three TCC cell line
Cell type Hystological type HSV-1 CPE efficacy Fusion efficacy Prodrug efficacy
(a)
EJ TCC + + +
T24 TCC + + 
RT112 TCC +  +
VMCUB-I TCC + + 
TCCSUP-G TCC +  +
5637 TCC + + +
KU19-19 TCC +  +
Cell line ED50 ED70 ED95
(b)
EJ 0.77±0.05 0.80±0.04 0.86±0.04
T24 0.65±0.07 0.61±0.04 0.73±0.07
KU19-19 0.78±0.01 0.58±0.06 0.57±0.08
(c)
EJ 2.6±0.12 2.29±0.01 2.11±0.01
T24 2.34±0.02 2.03±0.24 1.8±0.4
TCCSUPG 1.73±0.16 1.28±0.13 1.09±0.21
(d)
EJ 2.92±0.38 2.08±0.24 1.53±0.24
T24 1.54±0.43 0.89±0.22 0.59±0.12
TCCSUPG 1.42±0.13 1.18±0.47 1.18±0.78
Abbreviations: CPE¼ cytopathic effect; HSV¼ herpes simplex virus; TCC¼ transitional cell cancer. The effect of the combination of OncovexGALV/CD and chemotherapy on cell
proliferation was assessed by calculating combination index (CI) values using CalcuSyn software (Biosoft). Derived from the median-effect principle of Chou and Talalay, the CI
provides a quantitative measure of the degree of interaction between two or more agents. A CI of 1 denotes an additive interaction, 41 antagonism, and o1 synergy.
Experiments were done as described for the in vitro survival assay using 4, 2, 1, 0.5, and 0.25 times the calculated ED50 of each agent in a constant ratio checkerboard design.
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cell death. Results showed that in EJ cells infected either with
OncovexGALV/CD or OncovexGFP, cytotoxic cell death can be
blocked almost totally by inhibiting the caspase cascade
(Figure 4B), suggesting that both viruses cause cell death by an
apoptotic pathway. Apoptosis is mediated by caspase protease
activation and requires ATP (Rosser and Gores, 1995; Nicotera
et al, 1998; Bernardi et al, 1999). Necrosis results from ATP
depletion (Rosser and Gores, 1995; Green and Reed, 1998). Adding
fructose to cells generates ATP through glycolysis, which is
sufficient to inhibit necrotic cell death (Anundi and de, 1989). To
investigate this necrotic component, EJ cells were infected with
OncovexGALV/CD or OncovexGFP and incubated for 24/48 h. Our
results indicate that the presence of fructose enhanced cell death
rather than inhibiting it in EJ cells infected with OncovexGALV/CD
(and to a lesser extent in OncovexGFP) (Figure 4C). The positive
control for this experiment was Ionomycin that cause primary
necrosis (Gwag et al, 1999), which can be rescued by 20mM
fructose (data not shown). This suggests that the cytotoxicity was
controlled by a non-necrotic pathway and that the fructose was
feeding the apoptotic pathway. This hypothesis was confirmed by
the fact that fructose enhances cell death and can be blocked by
Z-VAD fmk (Figure 4D). Taken as a whole, this data suggests that
OncovexGALV/CD cell death is a purely apoptotoic-driven pathway
rather than through necrosis/autophagy as seen during transfec-
tion of viral fusogenic membrane GALV (Lin et al, 2010).
Treatment of a rat orthotopic bladder tumour model with
OncovexGALV/CD with or without 5-FC
To model in vivo human SBC, a rat orthotopic bladder tumour
model was used that was previously described by Xiao et al (1999).
AY-27 cells are a rat bladder transitional cell carcinoma cell line,
which was established as a primary bladder tumour in Fischer f344
rats, which were feed FANFT (N(4-(5-Nitro-2-Furyl)-2-Thiazolyl
Formamide) (Xiao et al, 1999). Histological examination of the
in vitro and in vivo tumour specimens confirmed the presence of
grade II-III transitional cell carcinoma (Xiao et al, 1999). AY-27
cells, which were previously tested for susceptibility for HSV
replication were used in this model. AY-27 cells were stably
transfected with the herpes virus entry receptor (HVEM) and a
clone selected that supported infection with HSV. Fusion assay
results showed a reduction in metabolic enzyme activity of
up to 30% (MTS assay) in AY-27 HVEM cells infected with
OncovexGALV/CD compared with the OncovexGFP control (Supple-
mentary Figure S1). This is in addition to the cytotoxcity seen with
HSV replication alone. AY-27 HVEM cells were further tested in
our prodrug assay, which showed that OncovexGALV/CD can meta-
bolise 5-FC within these cells, resulting in a decrease in metabolic
enzyme activity of up to 81% (MTS assay) when compared with
controls (Supplementary Figure S1). To facilitate tumour seeding,
the bladder mucosa was conditioned with an acid rinse followed by
neutralisation with alkali. After tumour seeding, a high success
rate of implantation was seen (495%). Figure 5D shows an
example of such an in vivo experiment (without treatment) where
tumours were seeded and the bladder removed at necropsy after 18
days. The first three bladders showed a high tumour load (Figures
5D, 1, 2 and 3). The fourth bladder was a control in which bladder
mucosa was conditioned (acid/alkali rinse) but no cells were seeded
(Figure 5D, 4). The tumour implantation procedure was well
tolerated by the animals. To study the effects of OncovexGALV/CD
in vivo, freshly harvested AY-27 HVEM cells were installed as
described above (day 0). The tumour-bearing animals were
assigned into three treated groups either OncovexGALV/CDþ 5-FC
(n¼ 10), OncovexGALV/CD þPBS (n¼ 10) or PBSþ 5-FC (control
group) (n¼ 8). Intravesical treatment of implanted tumours was
carried out with virus (OncovexGALV/CD, 9e7 pfu) or control PBS on
days 7, 14, and 21. Prodrug 5-FC (12.5mgml–1) or PBS was
installed in the same manner on days 8, 9, 15, 16, 22, and 24 and
the animals were killed on day 28. Bladders were removed and
assessed for tumour growth. The results showed an 84.5%
reduction in average tumour volume in the presence of both
OncovexGALV/CD and prodrug when compared with control
(P¼ 0.001) or virus alone P¼ 0.034) (Figure 5A). A smaller
amount of tumour shrinkage seen with virus alone was not
statistically significant when compared with control animals
(46.4% tumour reduction), (P¼ 0.13) (Figure 5A). In the control
groups, no spontaneous tumour regression was seen. The bladders
were weighed and showed a trend of lower bladder weight after
treatment with both agents (Figure 5C). On average, the animals
treated with OncovexGALV/CD þ 5-FC were 11.5 g heavier than
controls, suggesting that they were in a healthy condition
compared with controls (Figure 5B). The results strongly suggest
that a combination of oncolysis, prodrug activation and fusogenic
glycoprotein therapy offers an opportunity for improved tumour
control within the bladder.
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Figure 3 Oncolytic HSV viral replication in the presence of viral
glycoprotein, 5-FC and metabolites of 5-FC. (A) EJ cells were infected at
various MOI (0.001 0.0001) with either OncovexGFP or OncovexGALV/CD
and incubated at 37 1C for 48 h. Unpaired student t-test comparing GFP vs
GALV/CD P-value (MOI 0.001) 0.000 (MOI 0.0001) 0.0002. (B) EJ cells
were infected at various MOIs (0.1, 0.01, 0.001) with OncovexGALV/CD
in the presence or absence of 5-FC and incubated at 37 1C for 48 h.
þ or – 5-FC P-value (MOI 0.1) 0.03 (MOI 0.01) 0.414 (MOI 0.001) 0.075.
(C) EJ cells were infected at various MOIs (0.1, 0.01. 0.001) with
OncovexGALV/CD in the presence or absence of metabolites of 5-FC
and incubated at 37 1C for 48 h. The resulting virus stocks were titred
on BHK cells using a standard plaque assay þ or – metabolites of 5-FC
P-value (MOI 0.1) 0.005 (MOI 0.01) 0.004 (MOI 0.001) 0.0001.
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Computed microtomography (microCT) imaging of an
orthotopic bladder tumour model, during treatment with
OncovexGALV/CD þ 5-FC
For the orthotopic in vivo experiments, there was no way of
establishing how much tumour was present until autopsy. An
attempt was made to quantify tumour load by HVEM qPCR in
urine of implanted rats. The results showed no reliable signal was
detected that correlated to the amount of tumour present at
autopsy (data not shown). As a result, tumour growth was
evaluated by non invasive imaging using IVIS, by inserting the
insect luciferase gene into AY-27 HVEM cells. When these cells
were assessed in vivo (Fischer F344 flank model), a luciferase
signal was detected initially but faded due to regression of the
tumour (data not shown). To overcome this problem, microCT
was used with the aim of establishing the feasibility of imaging the
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Figure 4 Bladder TCC cells follow apoptotic pathway after infection with OncovexGALV/CD. (A) EJ cells were infected with OncovexGFP or
OncovexGALV/CD (MOI 1) with or without 5-FC (600mM) or its metabolites for 24, 48, and 72 h. Caspase activity was detected using Caspase Glo 3/7
reagent (Promega). Unpaired student t-test comparing GFP vs GALV/CD P-value 24 h 0.8919 48 h 0.2596 72 h 0.061. (B) EJ cells were infected
OncovexGALV/CD or OncovexGFP at MOIs of 1, 0.1 and then incubated with and without 50 uM Z-VAD-FMK (Sigma) for 48/72 h. After which, the
supernatant of the samples were assayed for lactate dehydrogenase activity (LDH) a marker of cytotoxic cell death (Roche). (C) EJ cells were infected with
OncovexGALV/CD or OncovexGFP at MOIs of 1, 0.1 and then incubated with and without 20mM fructose and incubated for 48/72 h at 37 1C. LDH assays
were carried out on sample supernatant. (D) EJ cells were infected with OncovexGALV/CD at MOIs of 1, 0.1 and then incubated with either 50mM Z-VAD-
FMK or 20mM fructose or both and incubated/assayed as above (unpaired student t-test comparing P-value Onc vs Onc ZVAD, 48 h MOI 1 P40.0000,
MOI 0.1 P 0.0127, 72 h MOI 1 P40.0000, MOI 0.1 P 0.000. GALV vs GALV ZVAD 48 h MOI 1 P40.0000, MOI 0.1 P40.0000, 72 h MOI 1 P40.0001,
MOI 0.1 P40.0000. Onc vs Onc Fru, 48 h MOI 1 P0.0078, MOI 0.1 P 0.0032, 72 h MOI 1 0.0051, MOI 0.1 0.3229, GALV vs GALV Fru 48 h MOI 1
P40.0015, MOI 0.1 P40.0001, 72 h MOI 1 0.0595, MOI 0.1 0.0148).
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tumours non-invasively while they were growing and the process
of oncolysis/prodrug activation within the bladder of Fischer F344
rats. These rats were implanted with freshly harvested AY-27
HVEM cells. On day 5 (Figure 6) after implantation, a catheter was
inserted into the bladder via the urethra with the use of an 18-
gauge plastic intravenous cannula (BD Venflon Pro, Oxford, UK),
which had been prefilled with iodine contrast (50% iodine contrast
in PBS). The bladder was filled with iodine contrast solution and
then the animal was scanned on a SkyScan1076 in vivo micro CT
(Scan parameter: 35mcm per slice, 68 kV, range of detector motion
192 degrees, 0.5mm aluminium filter). Further scans were carried
out on day 11, 15, 22, and 29 using the same method (Figure 6).
Intravesical treatment of implanted tumours was carried out with
virus (OncovexGALV/CD, 9e7 pfu) (or control PBS) on days 6, 12,
and 18. Prodrug 5-FC (12.5mgml–1) was installed in the same
manner on days 7, 8, 13, 14, 19, and 20 and the animals were killed
on day 29. Tumours were observed in animal A, which had
received no virus treatment (PBS)þ 5-FC. This animal can be
described as having disease progression, which filled the bladder
with tumour over the course of the experiment (Figure 6). The
presence of a large amount of tumours was confirmed by histology
using H&E stain (Figure 5E i). The tumour was also shown to be
proliferating using Ki67 staining (Figure 5F i). Animals B and F
received OncovexGALV/CD þ 5-FC treatment as described above.
Animal B had similar initial tumour load to animal A and showed a
complete response of pedunculated intraluminal disease (Figure 6).
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Figure 5 Treatment of a rat orthotopic bladder tumour model with OncovexGALV/CD þ 5-FC. AY-27 HVEM cells were implanted into the bladders of
female Fischer F344 rats at day 0. The tumour-bearing animals were assigned into three treatment groups either OncovexGALV/CDþ 5-FC (n¼ 10),
OncovexGALV/CD þ PBS (n¼ 10) or PBSþ 5-FC (control group) (n¼ 8). Intravesical treatment of implanted tumours was carried out with virus
(OncovexGALV/CD, 9e7 pfu) or control PBS on days 7, 14, and 21. Prodrug 5-FC (12.5mgml – 1) or PBS was installed in the same manner on days 8, 9, 15, 16,
22, and 24 and the animals were killed on day 28. Their bladders were removed and assessed for tumour abundance. The harvested bladders were weighed,
then opened up and the bladder surface, which macroscopically contained tumour was measured with a caliper. Average tumour volume was calculated by
measuring length x width/2. (A) Average tumour volume (B) Average body weight (C) Average bladder weight (unpaired student t-test comparing tumour
volume PBS vs GALV/CD þ 5-FC P¼ 0.001, PBS GALV/CD- 5-FC vs GALV/CD þ 5-FC P¼ 0.034, PBS vs GALV/CD 5-FC P¼ 0.13. (D) Bladder seeded
with tumour cells (no treatment) and removed at necropsy after 18 days (1, 2 and 3). Bladder 4 was a control in which bladder mucosa was conditioned
(acid/alkali rinse) but no cells were seeded. (E) H&E stain of sections from bladder from animals A (i) and B (ii). (F) Ki67 stain (brown) of sections from
bladder from animals A (i) and B (iii). No primary antibody control sections from animals A (ii) and B (iv).
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Histology (H&E stain) on this animal confirmed that almost no
tumour was present after treatment (Figure 5E ii). In the only small
area of disease identified in animal B, no proliferating tumour cells
were detected by Ki67 staining confirming a pathological complete
response. Animal F had a much higher initial tumour load than
both A or B at the start point of treatment, but still showed a
partial response in intraluminal pedunculated disease (Figure 6).
The results clearly show that it is possible to visualise the growth of
tumours and the process of oncolysis/prodrug activation in an
orthotopic bladder tumour model.
DISCUSSION
Surgery, BCG and chemotherapy dramatically slow the progress of
bladder cancer, but do not eradicate the disease totally (Sylvester
et al, 2006). BCG therapy is the reference standard in non-surgical
treatment for high-risk non-muscle invasive bladder cancer but is
associated with relatively high morbidity, with up to 25% of
patients failing to complete a full maintenance course. Clearly,
there is a need to develop new treatment strategies for bladder
cancer, particularly for high-risk superficial tumours with BCG
treatment failure and muscle invasive cancer.
In our study, we have shown that this viral-based triple therapy
offers a novel approach to intravesical treatment of bladder cancer.
Our choice of an oncolytic HSV, based on experience with
OncovexGALV/CD, has been found to be effective in treating various
experimental cancers while maintaining an excellent safety profile
(Simpson et al, 2006; Price et al, 2010; Wong et al, 2010).
The panel of cell lines were selected for the study because they
represent human bladder cancer with RT112 cells specifically
reflecting non-muscle invasive disease. All human bladder tumour
cell lines tested (in vitro) were susceptible to HSV oncolysis and
showed enhanced tumour cell killing with either fusion or prodrug
therapy (or both) when infected with OncovexGALV/CD virus.
Fusion therapy could enhance HSV oncolysis by decreasing
tumour TCC cell survival by up to 54%. Prodrug therapy from
OncovexGALV/CD, also killed (bystander effect) uninfected TCC by
up to 78%. A synergistic interaction was detected between
OncovexGALV/CD and the chemotherapy agent MMC but not
Cisplatin and Gemcitabine. Why is oncolytic HSV synergistic with
MMC but not cisplatin/gemcitabine on bladder TCC? Oncolytic
HSV-1 viruses have previously been shown to be synergistic with
MMC, (a potent cross-linker of DNA) on one bladder TCC cell line
(Mullerad et al, 2005) and a number of gastric cancer cell lines
(Bennett et al, 2004). In contrast, gemcitabine has previously been
shown to have limited synergy with HSV in pancreatic cancers cell
line, but this interaction does inhibit viral replication (Watanabe
et al, 2008). MMC is one of the range of DNA-damaging agents,
which induces the expression of GADD34 (growth arrest and DNA
damage –inducible protein) (review in Kanai et al, 2010). There
is a great homology between the carboxyl terminus of the
mammalian GADD34 gene and the corresponding carboxyl
domain of the viral ICP34.5/ virulence factor (Chou and Roizman,
1994), deletion of which allows tumour selective viral replication
(Rampling et al, 2000). RNAi targeting of GADD34 decreased
MMC -associated enhancement of HSV replication on gastric
cancer cell lines (Bennett et al, 2004). This would suggest that
MMC may upregulate GADD34 in HSV-infected TCC cells,
resulting in synergy between the two therapies. On this basis, we
would expect cisplatin to show synergy with HSV in bladder TCC
because cisplatin has been shown to upregulate GADD34 in
malignant mesothelioma and head/neck squamous carcinoma cell
lines (Adusumilli et al, 2006; Fishel et al, 2006). Our results do not
Day 5
Animal A
PBS
Animal B
OncGALV/CD + 5-FC
Animal B
OncGALV/CD + 5-FC
Animal F
OncGALV/CD + 5-FC
Animal F
OncGALV/CD + 5-FC
11 15 22 29
Figure 6 Computed tomography imaging of an orthotopic bladder tumour model during treatment with OncovexGALV/CD þ 5-FC. Intravesical
treatment of implanted tumours was carried out with virus (OncovexGALV/CD, 9e7 pfu) (or Control PBS) on days 6, 12, and 18. Prodrug 5-FC (12.5mgml –
1) was installed in the same manner on days 7, 8, 13, 14, 19, and 20 and the animals were killed on day 29. During the experiment, computed tomography
imaging was carried out on days 5, 11, 15, 22, and 29.
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show synergy between cisplatin and oncolytic HSV on bladder
TCC cells. Therefore, we can hypothesise that the cellular
components needed for upregulation of GADD34 by cisplatin are
present in malignant mesothelioma and head/neck squamous
carcinoma cell lines but may not be present in bladder TCC cells.
To study the effect of OncovexGALV/CD in vivo, we further
developed an orthotopic rat bladder model and confirmed safety,
efficacy, and ease of delivery of oncolytic viral therapy for
experimental treatment of bladder cancer. OncovexGALV/CD virus,
when administered with prodrug weekly for 3 weeks by
intravesical instillation, was clearly more effective than control
or virus alone at reducing tumour burden (84.5% reduction,
P¼ 0.001). To evaluate the in vivo orthotopic tumour growth and
then oncolysis, we tried non-invasive imaging including IVIS and
CT scanning. Using intravesical iodine contrast and CT scanning,
we were able to visualise the growth of tumours and oncolysis
following OncovexGALV/CD treatment.
A range of viral non-replicating vectors and oncolytic viruses
have been studied in both mouse and rat orthotopic bladder
tumour models. Non-replicating vectors such as lentivirus
(Kikuchi et al, 2004; Adam et al, 2007), adenovirus (Werthman
et al, 1996; Sutton et al, 2000) and poxviruses (Fodor et al, 2005)
have shown strong therapeutic gene expression in bladder cancer
including endostatin (Shichinohe et al, 2001) and p53 (Ruifa et al,
2006). Oncolytic viruses such as retroviral (RCR) vectors (Kikuchi
et al, 2007), adenovirus (Wang et al, 2006), VSV (Hadaschik et al,
2008), reovirus (Hanel et al, 2004), vaccinia virus (Fodor et al,
2005) and HSV-1 (Cozzi et al, 2001) offer bladder tumour selective
killing due to viral replication and even stronger therapeutic gene
expression due to multiple rounds of replication and promoter
upregulation (Hadaschik et al, 2008). These viral orthotopic
bladder studies have shown some efficacy, but only a few of these
viral vectors have gone on to clinical trials. Those that have include
adenovirus (Kuball et al, 2002; Pagliaro et al, 2003; Malmstrom
et al, 2010) and vaccinia virus (Gomella et al, 2001). Strong gene
transfer (WT p53, CD40L) has been seen using non replicating
adenovirus in patients biopsies, but only one clinical response was
seen in these early I/IIa trials (Kuball et al, 2002; Pagliaro et al,
2003; Malmstrom et al, 2010). In contrast, an oncolytic adenovirus
expressing GM-CSF (in combination with BCG) showed a response
rate of 46% as assessed by cytoscopy and urine cytology or biopsy
(McKiernan et al, 2009). Further studies have shown three out of
four patients treated with an oncolytic vaccinia virus have been
shown to be disease free after 4 years (McKiernan et al, 2009).
HSV-1, like vaccinia, is a large DNA virus, which can be easily
manipulated to allow tumour selective virus replication (MacLean
et al, 1991; Martuza et al, 1991; Rampling et al, 2000) and allows
insertion of therapeutic genes of up to 30 kb (Roizman and
Jenkins, 1985). Oncolytic HSV can infect a broad range of human
tumour cell types. It is a highly lytic virus, resulting in tumour cell
death, but does not integrate into the host genome avoiding the
possibility of activating proto-oncogenes.
We refined an existing rat orthotopic bladder tumour model to
evaluate the efficacy of the OncovexGALV/CD virus with or
without 5-FC. Advantages of a rat versus a mouse model include its
size and evidence that the rat model may represent the human
disease processes better than the mouse equivalent (Oyasu, 1995).
In these models, the traditional endpoints of tumour size are not
appropriate as the evolving intravesical tumour may block both
ureters and cause urinary obstruction and renal failure. We
therefore sought to establish a robust non-invasive method of
monitoring response to intravesical therapy. Other assessment
modalities have been used including urine cytology (Gronlund-
Pakkanen et al, 2003), ultrasound (Rooks et al, 2001), MRI
(Mazurchuk et al, 1997), qPCR (Wang et al, 2006) and
bioluminescence imaging (Ray and Gambhir, 2007). We were able
to closely monitor evolving tumour and response to treatment by
CT in animals with high and low tumour burdens.
We hope in the future to evaluate the in vivo orthotopic tumour
growth (and oncolysis), by using bioinformatics analysis of the CT
scanning data. We hope to obtain from this data, an accurate
measurement of the volume and density of the in vivo tumours.
The measure of tumour density will give an indication of the
presence of necrosis, which will help to establish a truer picture of
the efficacy of any oncolytic virus tested. We are negotiating with
the company Amgen as to its potential clinical application.
In conclusion, we found OncovexGALV/CD to be effective in vitro
and in treating an orthotopic rat bladder cancer. A version of this
virus expressing GM-CSF has shown promising results in phase I
and II (Hu et al, 2006; Senzer et al, 2009) with limited toxicity to
patients and is currently in phase III clinical trials in melanoma
and head and neck cancer. Our results suggest that OncovexGALV/CD
(þ 5-FC) intravesical therapy should be considered for human
application.
Statistics
The values of the experiments were presented as the mean±s.d.
(or s.e.) and analysis of variance was measured using unpaired
Student’s t-test. Statistical significance was determined at a P-value
o0.05.
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